PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.

Abstract To evaluate the diagnostic accuracy and prognostic performance of urinary and plasma levels of placental growth factor (PLGF) and provide their comparison with the results of vascular endothelial growth factor A (VEGF-A) in patients with primary and recurrent urinary bladder cancer.
PMID
Related Publications

Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction.

Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer.

Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors.

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer.

Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.

Authors

Mayor MeshTerms

Placenta Growth Factor

Urinary Bladder Neoplasms

Vascular Endothelial Growth Factor A

Keywords

Bladder cancer

ELISA

PLGF

VEGF-A

biomarker

non-invasive detection

placental growth factor

prognosis

vascular endothelial growth factor A

Journal Title anticancer research
Publication Year Start




PMID- 29277778
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and
      Prognostic Performance of Vascular Endothelial Growth Factor A.
PG  - 239-246
AB  - BACKGROUND/AIM: To evaluate the diagnostic accuracy and prognostic performance of
      urinary and plasma levels of placental growth factor (PLGF) and provide their
      comparison with the results of vascular endothelial growth factor A (VEGF-A) in
      patients with primary and recurrent urinary bladder cancer. MATERIALS AND
      METHODS: The enzyme-linked immunosorbent assay (ELISA) was used to assess urinary
      and plasma concentrations of PLGF and VEGF-A in 240 individuals. RESULTS: PLGF
      levels in urine and plasma were significantly higher in patients with primary
      bladder cancer than in healthy individuals (p=0.003, p=0.005, respectively). Area
      under the curve (AUC) of urinary PLGF was 0.68; AUC of plasma PLGF levels was
      0.65. Patients with the urine levels of PLGF higher than 82.33 pg/ml had three
      times higher risk of recurrence. In patients with recurrent bladder cancer, the
      urinary concentrations of PLGF did not significantly differ from the
      concentrations in patients without current disease (p=0.61). However, plasma PLGF
      levels were significantly higher in patients diagnosed with tumor recurrence
      (p=0.001); AUC of plasma PLGF levels was 0.69. Moreover, patients with plasma
      levels higher than 10.09 pg/ml had a five-times higher risk of future tumor
      recurrence. The diagnostic accuracy of PLGF was comparable with VEGF-A.
      CONCLUSION: From a clinical point of view, PLGF could be considered a valid
      diagnostic test for the detection of primary and recurrent bladder cancer. In
      patients with recurrent bladder cancer, plasma PLGF levels can differentiate
      individuals at risk of tumor recurrence.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Soukup, Viktor
AU  - Soukup V
AD  - Department of Urology, the First Faculty of Medicine, Charles University and
      General University Hospital, Prague, Czech Republic [email protected]
FAU - Capoun, Otakar
AU  - Capoun O
AD  - Department of Urology, the First Faculty of Medicine, Charles University and
      General University Hospital, Prague, Czech Republic.
FAU - Pesl, Michael
AU  - Pesl M
AD  - Department of Urology, the First Faculty of Medicine, Charles University and
      General University Hospital, Prague, Czech Republic.
FAU - Sobotka, Roman
AU  - Sobotka R
AD  - Department of Urology, the First Faculty of Medicine, Charles University and
      General University Hospital, Prague, Czech Republic.
FAU - Vavrova, Lucie
AU  - Vavrova L
AD  - Department of Urology, the First Faculty of Medicine, Charles University and
      General University Hospital, Prague, Czech Republic.
FAU - Hanus, Tomas
AU  - Hanus T
AD  - Department of Urology, the First Faculty of Medicine, Charles University and
      General University Hospital, Prague, Czech Republic.
FAU - Zima, Tomas
AU  - Zima T
AD  - Institute of Medical Biochemistry and Laboratory Diagnostics, the First Faculty
      of Medicine, Charles University and General University Hospital, Prague, Czech
      Republic.
FAU - Kalousova, Marta
AU  - Kalousova M
AD  - Institute of Medical Biochemistry and Laboratory Diagnostics, the First Faculty
      of Medicine, Charles University and General University Hospital, Prague, Czech
      Republic.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 144589-93-5 (Placenta Growth Factor)
SB  - IM
MH  - Humans
MH  - Neoplasm Recurrence, Local/blood/diagnosis/urine
MH  - *Placenta Growth Factor/blood/urine
MH  - Prognosis
MH  - *Urinary Bladder Neoplasms/blood/diagnosis/urine
MH  - *Vascular Endothelial Growth Factor A/blood/urine
OTO - NOTNLM
OT  - *Bladder cancer
OT  - *ELISA
OT  - *PLGF
OT  - *VEGF-A
OT  - *biomarker
OT  - *non-invasive detection
OT  - *placental growth factor
OT  - *prognosis
OT  - *vascular endothelial growth factor A
EDAT- 2017/12/27 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/28 00:00 [received]
PHST- 2017/11/08 00:00 [revised]
PHST- 2017/11/09 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
AID - 38/1/239 [pii]
AID - 10.21873/anticanres.12213 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):239-246. doi: 10.21873/anticanres.12213.